Patients + Caregivers

Changing the future of cancer: YOU are not alone

Every year two million Americans leave their doctor’s offices with a cancer diagnosis, changing the course of their lives. In spite of recent treatment advances, over 600,000 Americans die every year from cancer.  

We imagine a world where next-generation precision radiopharmaceuticals are available to every cancer patient, making them a pillar of cancer care.

A couple standing together, smiling.


Radioligands graphic

Radioligands are like microscopic, cancer-seeking missiles. Also known as Radioligand Therapy or RLT, they are modern radiopharmaceuticals actively used to diagnose and treat cancers such as non-Hodgkins lymphoma, neuroendocrine tumours (NETs), and prostate cancer.

Radioligand Therapy (RLT)

Radioligands Therapy graphic

Compared to chemotherapy, which is not a targeted therapy and can cause extensive damage to healthy tissue and organs, radioligands precisely deliver radiation to tumors,  damaging the cancer cells while avoiding surrounding tissues.

What to expect from radioligand therapy

Talk to your doctors

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. We are currently in the research and development phase and do not have any approved products which can be offered for prescription or sale.

We are currently conducting clinical trials to evaluate the safety and efficacy of many of the programs in our pipeline. Talk to your doctor about whether participating in a clinical trial is right for you.

Clinical trials

Learn more about our ongoing studies.